Literature DB >> 29533778

ORY-1001: Overcoming the Differentiation Block in AML.

Prithviraj Bose1, Marina Y Konopleva2.   

Abstract

In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001-an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)-in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29533778     DOI： 10.1016/j.ccell.2018.02.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

Review 1.  Epigenetic memory in development and disease: Unraveling the mechanism.

Authors:  Sam Thiagalingam
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-01-23       Impact factor: 10.680

Review 2.  Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.

Authors:  Kunal Nepali; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2021-04-12       Impact factor: 8.410

3.  Hydrophilic Realgar Nanocrystals Prolong the Survival of Refractory Acute Myeloid Leukemia Mice Through Inducing Multi-Lineage Differentiation and Apoptosis.

Authors:  Tao Wang; Xue Zhang; Mengfan Jia; Aiyun Yang; Jian Liu; Tao Wen; Jie Meng; Haiyan Xu
Journal:  Int J Nanomedicine       Date:  2022-05-16

Review 4.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 5.  LSD1/KDM1A inhibitors in clinical trials: advances and prospects.

Authors:  Yuan Fang; Guochao Liao; Bin Yu
Journal:  J Hematol Oncol       Date:  2019-12-04       Impact factor: 17.388

Review 6.  Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation.

Authors:  Florian Perner; Scott A Armstrong
Journal:  Cells       Date:  2020-12-21       Impact factor: 6.600

7.  Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?

Authors:  Pedro A Lazo
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

8.  Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer.

Authors:  Rosaria Benedetti; Carmela Dell'Aversana; Tommaso De Marchi; Dante Rotili; Ning Qing Liu; Boris Novakovic; Serena Boccella; Salvatore Di Maro; Sandro Cosconati; Alfonso Baldi; Emma Niméus; Johan Schultz; Urban Höglund; Sabatino Maione; Chiara Papulino; Ugo Chianese; Francesco Iovino; Antonio Federico; Antonello Mai; Hendrik G Stunnenberg; Angela Nebbioso; Lucia Altucci
Journal:  Cancers (Basel)       Date:  2019-12-16       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.